Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business
The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.
The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.